for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ギリアド・サイエンシズ・インク

GILD.O

現在値

67.35USD

変化

0.74(+1.11%)

出来高

5,310,414

本日のレンジ

66.77

 - 

67.56

52週レンジ

56.56

 - 

78.94

∙ 約20分前の相場を表示しています。

適時開示

Kite And Shoreline Biosciences Enter Into Partnership To Develop Novel Allogeneic Cell Therapies

June 17 (Reuters) - :KITE AND SHORELINE BIOSCIENCES ENTER INTO STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES.KITE SAYS SHORELINE TO RECEIVE UPFRONT PAYMENT, ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS OF OVER $2.3 BILLION, AND ROYALTIES.KITE SAYS AGREEMENT FOLLOWS KITE’S INVESTMENT IN SHORELINE’S RECENT SERIES A FINANCING.Further company coverage: GILD.O. ((Reuters.Briefs@thomsonreuters.com;)).

Jounce Therapeutics Achieves First Milestone In Exclusive License Agreement With Gilead Sciences

June 15 (Reuters) - Jounce Therapeutics Inc <JNCE.O>::JOUNCE THERAPEUTICS ACHIEVES FIRST MILESTONE IN EXCLUSIVE LICENSE AGREEMENT WITH GILEAD SCIENCES AND FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR ANTI-CCR8 ANTIBODY.JOUNCE THERAPEUTICS INC - IND CLEARANCE TRIGGERS A $25.0 MILLION MILESTONE PAYMENT TO JOUNCE..

EMA Recommends Change To Product Information For Remdesivir To Include Sinus Bradycardia As Adverse Reaction

June 11 (Reuters) - European Medicines Agency::EMA SAYS PRAC RECOMMENDED CHANGE TO PRODUCT INFORMATION FOR REMDESIVIR TO INCLUDE SINUS BRADYCARDIA AS ADVERSE REACTION OF UNKNOWN FREQUENCY FOR MEDICINE.EMA SAYS PRAC CONCLUDED THAT A CAUSAL RELATIONSHIP BETWEEN USE OF REMDESIVIR AND ADVERSE EVENT OF BRADYCARDIA IS AT LEAST A REASONABLE POSSIBILITY.EMA SAYS DHPC IS INTENDED TO INFORM HEALTHCARE PROFESSIONALS ABOUT OUTCOME OF A SIGNAL PROCEDURE AND NEW RECOMMENDATIONS FOR USE OF XELJANZ.EMA SAYS PRAC ADVISING XELJANZ BE USED IN PATIENTS OVER 65 YRS, CURRENT/PAST SMOKERS, OTHER CARDIOVASCULAR RISK FACTORS IF NO SUITABLE ALTERNATIVE AVAILABLE.Further company coverage: GILD.O. ((Reuters.Briefs@thomsonreuters.com;)).

U.S. Food And Drug Administration Approves New Formulation Of Epclusa

June 10 (Reuters) - Gilead Sciences Inc <GILD.O>::U.S. FOOD AND DRUG ADMINISTRATION APPROVES NEW FORMULATION OF EPCLUSA®, EXPANDING PEDIATRIC INDICATION TO TREAT CHILDREN AGES 3 AND OLDER WITH CHRONIC HEPATITIS C.GILEAD SCIENCES INC - FDA APPROVAL FOR EPCLUSA INCLUDES BOXED WARNING.GILEAD SCIENCES INC - FDA APPROVED A NDA FOR TWO STRENGTHS OF AN ORAL PELLET FORMULATION OF EPCLUSA.

Trodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study

June 4 (Reuters) - Gilead Sciences Inc <GILD.O>::TRODELVY® DEMONSTRATES SUPERIOR OUTCOMES TO STANDARD OF CARE IN SECOND-LINE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN PHASE 3 ASCENT STUDY.GILEAD SCIENCES - TRODELVY IMPROVED PROGRESSION-FREE SURVIVAL (PFS), WITH A 59% REDUCTION IN THE RISK OF DISEASE WORSENING OR DEATH.GILEAD SCIENCES - ADDITIONAL RESULTS SHOWED TRODELVY DEMONSTRATED A HIGHER OVERALL RESPONSE RATE COMPARED WITH CHEMOTHERAPY.GILEAD SCIENCES - SAFETY PROFILE OF TRODELVY IN SUBGROUP WAS CONSISTENT WITH PRIOR REPORTS.Further company coverage: GILD.O. ((Reuters.Briefs@thomsonreuters.com;)).

Legal & General fund unit seeks split of Gilead Sciences CEO/Chair roles

May 6 (Reuters) - Gilead Sciences Inc <GILD.O>::LEGAL & GENERAL INVESTMENT MANAGEMENT SAYS HAS CO-FILED SHAREHOLDER RESOLUTION CALLING FOR SEPARATION OF CEO AND CHAIR ROLES AT GILEAD SCIENCES.Further company coverage: GILD.O. (Reporting By Carolyn Cohn). ((carolyn.cohn@thomsonreuters.com;)).

Gilead Sciences Announces Steps To Expand Availability Of Remdesivir In India

April 26 (Reuters) - Gilead Sciences Inc <GILD.O>::GILEAD SCIENCES ANNOUNCES STEPS TO EXPAND AVAILABILITY OF REMDESIVIR IN INDIA.GILEAD SCIENCES INC - WILL DONATE A MINIMUM OF 450,000 VIALS OF VEKLURY(®) TO GOVERNMENT OF INDIA.GILEAD SCIENCES INC - COMMITTED TO PROVIDING SUPPORT TO VOLUNTARY LICENSEES BASED OUTSIDE OF INDIA TO INCREASE THEIR PRODUCTION CAPACITY.GILEAD - PLANNED SUPPORT TO VOLUNTARY LICENSEES BASED OUTSIDE OF INDIA WILL INCLUDE DONATION OF API TO LICENSEES WITH A VIEW TO ACCELERATE PRODUCTION.GILEAD - CO'S LICENSEES BASED IN INDIA SIGNIFICANTLY ACCELERATED PRODUCTION OF REMDESIVIR, WHICH IS EXPECTED TO INCREASE ITS AVAILABILITY IN COMING WEEKS.

NIH Says Clinical Trial Of Therapeutics For Severely Ill Hospitalized COVID-19 Patients Begins

April 22 (Reuters) - :NIH - CLINICAL TRIAL OF THERAPEUTICS FOR SEVERELY ILL HOSPITALIZED COVID-19 PATIENTS BEGINS.NIH - TRIAL WILL BEGIN BY TESTING ZYESAMI AND REMDESIVIR (VEKLURY).NIH - TRIAL WILL TEST ZYESAMI AND REMDESIVIR (ALONE AND IN COMBINATION), FOR THEIR SAFETY AND EFFICACY IN HOSPITALIZED COVID-19 PATIENTS.

Humanigen Reports Positive Data With Lenzilumab In The Zuma-19 CAR-T Phase 1B Study In DLBCL And Plans To Initiate Potential Registrational Study

April 19 (Reuters) - Humanigen Inc <HGEN.O>::HUMANIGEN REPORTS POSITIVE DATA WITH LENZILUMAB IN THE ZUMA-19 CAR-T PHASE 1B STUDY IN DLBCL AND PLANS TO INITIATE A POTENTIAL REGISTRATIONAL STUDY.HUMANIGEN INC - LENZILUMAB REDUCED IL-6, CRP, FERRITIN, MCP-1, IL-8, AND IP-10 (CXCL-10) AMONG OTHERS.HUMANIGEN - PLANS TO CONDUCT PHASE 2 STUDY WITH LENZILUMAB COMBINED WITH ALL COMMERCIALLY AVAILABLE CD19 CAR-T THERAPIES IN DLBCL.HUMANIGEN INC - TERMINATED ZUMA-19 CLINICAL COLLABORATION AGREEMENT WITH KITE, A GILEAD COMPANY.HUMANIGEN INC - AT RECOMMENDED PHASE 2 DOSE, LENZILUMAB IN COMBINATION WITH CAR-T, DEMONSTRATED A 100% OBJECTIVE RESPONSE RATE.

Everest Medicines Says US FDA Granted Accelerated Approval Of Trodelvy To Gilead Sciences

April 14 (Reuters) - Everest Medicines Ltd <1952.HK>::US FDA GRANTED ACCELERATED APPROVAL OF TRODELVY TO GILEAD SCIENCES FOR TREATMENT OF METASTATIC UROTHELIAL CANCER.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up